Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
7. A method of treating acute myeloid leukemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
8. A method of treating gastrointestinal stromal tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
9. A method of treating mastocytosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.